The multitasking mast cell: Positive and negative roles in the progression of autoimmunity

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 2673-2679

  Christy, Alison L ^a   Brown, Melissa A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; CYTOKINE; HISTAMINE; HYDROXYZINE; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; LEUKOTRIENE; NERVE GROWTH FACTOR; PROSTAGLANDIN; PROTEINASE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLERGIC ENCEPHALITIS; ALLERGY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAST CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SHORT SURVEY; T LYMPHOCYTE; ANIMAL; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; HUMANS; MAST CELLS; MICE; MULTIPLE SCLEROSIS; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 36849043756     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.2673     Document Type: Short Survey

References (111)

1. Kindt, T. J., R. A. Goldsby, and B. A. Osborne. 2007. Kuby Immunology, 6th Ed. W.H. Freeman, New York.
2. Crivellato, E., C. Beltrami, F. Mallardi, and D. Ribatti. 2003. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br. J. Haematol. 123: 19-21.
3. Metz, M., M. A. Grimbaldeston, S. Nakae, A. M. Piliponsky, M. Tsai, and S. J. Galli. 2007. Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev. 217: 304-328.
4. Nakae, S., H. Suto, M. Iikura, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176: 2238-2248.
5. McCurdy, J. D., T. J. Olynych, L. H. Maher, and J. S. Marshall. 2003. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170: 1625-1629.
6. Gregory, G. D., S. S. Raju, S. Winandy, and M. A. Brown. 2006. Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. J. Clin. Invest. 116: 1327-1336.
7. Bebo, B. F., Jr., C. H. Lee, E. L. Orr, and D. S. Linthicum. 1996. Mast cell-derived histamine and tumour necrosis factor: differences between SJL/J and BALB/c inbred strains of mice. Immunol. Cell Biol. 74: 225-230.
8. d mice: Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am. J. Pathology. 127: 191-198.
9. Grimbaldeston, M. A., C. C. Chen, A. M. Piliponsky, M. Tsai, S. Y. Tam, and S. J. Galli. 2005. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 167: 835-848.
10. Nigrovic, P. A., and D. M. Lee. 2007. Synovial mast cells: role in acute and chronic arthritis. Immunol. Rev. 217: 19-37.
11. Nelson, K. C., M. Zhao, P. R. Schroeder, N. Li, R. A. Wetsel, L. A. Diaz, and Z. Liu. 2006. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J. Clin. Invest. 116: 2892-2900.
12. Lin, L., A. J. Gerth, and S. L. Peng. 2004. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol. Lett. 91: 93-97.
13. Esposito, I., J. Kleeff, S. C. Bischoff, L. Fischer, P. Collecchi, M. Iorio, G. Bevilacqua, M. W. Buchler, and H. Friess. 2002. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab. Invest. 82: 1481-1492.
14. Zimnoch, L., B. Szynaka, and Z. Puchalski. 2002. Mast cells and pancreatic stellate cells in chronic pancreatitis with differently intensified fibrosis. Hepatogastroenterology 49: 1135-1138.
15. Dib, M., X. Zhao, X. Wang, and R. Andersson. 2002. Mast cells contribute to early pancreatitis-induced systemic endothelial barrier dysfunction. Pancreatology 2: 396-401.
16. Dib, M., X. Zhao, X. D. Wang, and R. Andersson. 2002. Role of mast cells in the development of pancreatitis-induced multiple organ dysfunction. Br. J. Surg. 89: 172-178.
17. Esposito, I., H. Friess, A. Kappeler, S. Shrikhande, J. Kleeff, H. Ramesh, A. Zimmermann, and M. W. Buchler. 2001. Mast cell distribution and activation in chronic pancreatitis. Hum Pathol. 32: 1174-1183.
18. + T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA 99: 12287-12292.
19. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200: 277-285.
20. Belghith, M., J. A. Bluestone, S. Barriot, J. Megret, J. F. Bach, and L. Chatenoud. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208.
21. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
22. Steinman, L. 1996. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302.
23. Sriram, S., and I. Steiner. 2005. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 58: 939-945.
24. Steinman, L., and S. S. Zamvil. 2005. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26: 565-571.
25. Wheeler, R. D., and T. Owens. 2005. The changing face of cytokines in the brain: perspectives from EAE. Curr. Pharm. Des. 11: 1031-1037.
26. Steinman, L., and S. S. Zamvil. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60: 12-21.
27. Bettelli, E., M. Oukka, and V. K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8: 345-350.
28. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavriela, and K. M. Murphy. 2006. Th17: an effector CD4 cell lineage with regulatory T cell ties. Immunity 24: 677-688.
29. Gregory, G. D., A. Bickford, M. Robbie-Ryan, M. Tanzola, and M. A. Brown. 2005. MASTering the immune response: mast cells in autoimmunity. Novartis Found. Symp. 271: 215-225; discussion 225-231.
30. Brenner, T., D. Soffer, M. Shalit, and F. Levi-Schaffer. 1994. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J. Neurol. Sci. 122: 210-213.
31. Johnson, D., D. Yasui, and P. Seeldrayers. 1991. An analysis of mast cell frequency in the rodent nervous system: Numbers vary between different strains and can be reconstituted in mast cell-deficient mice. J. Neuropathol. Exp. Neurol. 50: 227-234.
32. Dietsch, G. N., and D. J. Hinrichs. 1989. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. J. Immunol. 142: 1476-1481.
33. Secor, V. H., W. E. Secor, C. A. Gutekunst, and M. A. Brown. 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191: 813-822.
34. Tanzola, M. B., M. Robbie-Ryan, C. A. Gutekunst, and M. A. Brown. 2003. Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J. Immunol. 171: 4385-4391.
35. Gregory, G. D., M. Robbie-Ryan, V. H. Secor, J. J. Sabatino, Jr., and M. A. Brown. 2005. Mast cells are required for optimal autoreactive T cell responses in a murine model of multiple sclerosis. Eur. J. Immunol. 35: 3478-3486.
36. Neuman, J. 1890. Ueber das Vorkommen der sogneannten " Mastzellen" bei pathologischen Veraenderungen des Gehirns. Arch. Pathol. Anat. Physiol. Virchows 122: 378-381.
37. Toms, R., H. L. Weiner, and D. Johnson. 1990. Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. J. Neuroimmunol. 30: 169-177.
38. Ibrahim, M. Z., A. T. Reder, R. Lawand, W. Takash, and S. Sallouh-Khatib. 1996. The mast cells of the multiple sclerosis brain. J. Neuroimmunol. 70: 131-138.
39. Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8: 500-508.
40. Rozniecki, J. J., S. L. Hauser, M. Strein, R. Lincoln, and T. C. Theoharides. 1995. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann. Neurol. 37: 63-66.
41. Stelekati, E., Z. Orinska, and S. Bulfone-Paus. 2007. Mast cells in allergy: innate instructors of adaptive responses. Immunobiology 212: 505-519.
42. Johnson, D., P. A. Seeldrayers, and H. L. Weiner. 1988. The role of mast cells in demyelination. I. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation. Brain Res. 44: 195-198.
43. Ascherio, A., and K. L. Munger. 2007. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann. Neurol. 61: 288-299.
44. Seeldrayers, P. A., D. Yasui, H. L. Weiner, and D. Johnson. 1989. Treatment of experimental allergic neuritis with nedocromil sodium, an anti-inflammatory drug with mast cell stabilizing properties. J. Neuroimmunol. 25: 221-226.
45. Zappulla, J. P., M. Arock, L. T. Mars, and R. S. Liblau. 2002. Mast cells: new targets for multiple sclerosis therapy? J. Neuroimmunol. 131: 5-20.
46. Paniagua, R. T., O. Sharpe, P. P. Ho, S. M. Chan, A. Chang, J. P. Higgins, B. H. Tomooka, F. M. Thomas, J. J. Song, S. B. Goodman, et al. 2006. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116: 2633-2642.
47. Zoja, C., D. Corna, D. Rottoli, C. Zanchi, M. Abbate, and G. Remuzzi. 2006. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70: 97-103.
48. Logothetis, L., I. A. Mylonas, S. Baloyannis, M. Pashalidou, A. Orologas, A. Zafeiropoulos, V. Kosta, and T. C. Theoharides. 2005. A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis. Int. J. Immunopathol. Pharmacol. 18: 771-778.
49. Cose, S. 2007. T cell migration: a naive paradigm? Immunology 120: 1-7.
50. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
51. Kitawaki, T., N. Kadowaki, N. Sugimoto, N. Kambe, T. Hori, Y. Miyachi, T. Nakahata, and T. Uchiyama. 2006. IgE-activated mast cells in combination with proinflammatory factors induce Th2-promoting dendritic cells. Int. Immunol. 18: 1789-1799.
52. Jawdat, D. M., G. Rowden, and J. S. Marshall. 2006. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 177: 1755-1762.
53. Bryce, P. J., M. L. Miller, I. Miyajima, M. Tsai, S. J. Galli, and H. C. Oettgen. 2004. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20: 381-392.
54. Suto, H., S. Nakae, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2006. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 176: 4102-4112.
55. Yao, Y., W. Li, M. H. Kaplan, and C. H. Chang. 2005. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J. Exp. Med. 201: 1899-1903.
56. Ebner, S., V. A. Nguyen, M. Forstner, Y. H. Wang, D. Wolfram, Y. J. Liu, and N. Romani. 2007. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J. Allergy Clin. Immunol. 119: 982-990.
57. Caron, G., Y. Delneste, E. Roelandts, C. Duez, N. Herbault, G. Magistrelli, J. Y. Bonnefoy, J. Pestel, and P. Jeannin. 2001. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol. 166: 6000-6006.
58. 2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J. Immunol. 170: 4943-4952.
59. Theiner, G., A. Gessner, and M. B. Lutz. 2006. The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 211: 463-472.
60. Caron, G., Y. Delneste, E. Roelandts, C. Duez, J. Y. Bonnefoy, J. Pestel, and P. Jeannin. 2001. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J. Immunol. 167: 3682-3686.
61. Nakae, S., H. Suto, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2005. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc. Natl. Acad. Sci. USA 102: 6467-6472.
62. Sayed, B. A., and M. A. Brown. 2007. Mast cells as modulators of T-cell responses. Immunol. Rev. 217: 53-64.
63. Lu, L. F., E. F. Lind, D. C. Gondek, K. A. Bennett, M. W. Gleeson, K. Pino-Lagos, Z. A. Scott, A. J. Coyle, J. L. Reed, J. Van Snick, et al. 2006. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002.
64. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50.
65. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
66. Steinman, R. M., D. Hawiger, K. Liu, L. Bonifaz, D. Bonnyay, K. Mahnke, T. Iyoda, J. Ravetch, M. Dhodapkar, K. Inaba, and M. Nussenzweig. 2003. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. 987: 15-25.
67. Faria, A. M., and H. L. Weiner. 2006. Oral tolerance and TGF-β-producing cells. Inflamm. Allergy Drug Target 5: 179-190.
68. Carrier, Y., J. Yuan, V. K. Kuchroo, and H. L. Weiner. 2007. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-β T cell-transgenic mice. J. Immunol. 178: 179-185.
69. Cobbold, S. P., K. F. Nolan, L. Graca, R. Castejon, A. Le Moine, M. Frewin, S. Humm, E. Adams, S. Thompson, D. Zelenika, et al. 2003. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol. Rev. 196: 109-124.
70. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27: 68-73.
71. Bennett, C. L., and H. D. Ochs. 2001. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. 13: 533-538.
72. Malek, T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukocyte Biol. 74: 961-965.
73. + T regulatory cells. J. Immunol. 178: 4022-4026.
74. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172: 5213-5221.
75. 2-dependent mechanism. J. Immunol. 177: 246-254.
76. - T cells anergic and suppressive. Immunology 120: 447-455.
77. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199: 1401-1408.
78. Korn, T., J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Backstrom, R. A. Sobel, K. W. Wucherpfennig, T. B. Strom, et al. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13: 423-431.
79. + regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204: 191-201.
80. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169: 4712-4716.
81. + regulatory T cells. Immunology 121: 15-28.
82. + regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612.
83. Alvarado-Sanchez, B., B. Hernandez-Castro, D. Portales-Perez, L. Baranda, E. Layseca-Espinosa, C. Abud-Mendoza, A. C. Cubillas-Tejeda, and R. Gonzalez-Amaro. 2006. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 27: 110-118.
84. Ito, T., Y. H. Wang, O. Duramad, S. Hanabuchi, O. A. Perng, M. Gilliet, F. X. Qin, and Y. J. Liu. 2006. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 13138-13143.
85. Fife, B. T., I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203: 2737-2747.
86. Inobe, J., A. J. Slavin, Y. Komagata, Y. Chen, L. Liu, and H. L. Weiner. 1998. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28: 2780-2790.
87. + regulatory T cell-mediated suppression. J. Immunol. 176: 3900-3904.
88. Biedermann, T., S. Zimmermann, H. Himmelrich, A. Gumy, O. Egeter, A. K. Sakrauski, I. Seegmuller, H. Voigt, P. Launois, A. D. Levine, et al. 2001. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2: 1054-1060.
89. Jawdat, D. M., E. J. Albert, G. Rowden, I. D. Haidl, and J. S. Marshall. 2004. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J. Immunol. 173: 5275-5282.
90. Del Prete, A., W. H. Shao, S. Mitola, G. Santoro, S. Sozzani, and B. Haribabu. 2007. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109: 626-631.
91. Abbott, N. J. 2000. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell. Mol Neurobiol. 20: 131-147.
92. Englehardt, B. 2006. Molecular mechanisms involved in T cell migration across the blood brain barrier. J. Neural Transm. 113: 477-485.
93. + T cells through production of leukotriene B4. Nat. Immunol. 4: 974-981.
94. Benoist, C., and D. Mathis. 2002. Mast cells in autoimmune disease. Nature 420: 875-878.
95. Straub, R. H. 2007. Autoimmune disease and innervation. Brain Behav. Immun. 21: 528-534.
96. Brain, S. D. 2000. New feelings about the role of sensory nerves in inflammation. Nat. Med. 6: 134-135.
97. Vasko, M. 1999. Prostaglandin-induced neuropeptide release from spinal cord. Prog. Brain Res. 104: 367-380.
98. Villoslada, P., S. L. Hauser, I. Bartke, J. Unger, N. Heald, D. Rosenberg, S. W. Cheung, W. C. Mobley, S. Fisher, and C. P. Genain. 2000. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med. 191: 1799-1806.
99. Kessler, J. A., and I. B. Black. 1980. Nerve growth factor stimulates the development of substance P in sensory ganglia. Proc. Natl. Acad. Sci. USA 77: 649-652.
100. Dinh, Q. T., D. A. Groneberg, C. Peiser, J. Springer, R. A. Joachim, P. C. Arck, B. F. Klapp, and A. Fischer. 2004. Nerve growth factor-induced substance P in capsaicin-insensitive vagal neurons innervating the lower mouse airway. Clin. Exp. Allergy 34: 74-1479.
101. Ralph, J. A., D. Zocco, B. Bresnihan, O. Fitzgerald, A. N. McEvoy, and E. P. Murphy. 2007. A role for type 1α corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am. J. Pathol. 170: 1121-1133.
102. Kokkotou, E., D. Torres, A. C. Moss, M. O'Brien, D. E. Grigoriadis, K. Karalis, and C. Pothoulakis. 2006. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J. Immunol. 177: 3355-3361.
103. Kalantaridou, S., A. Makrigiannakis, E. Zoumakis, and G. P. Chrousos. 2007. Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front. Biosci. 12: 572-580.
104. Cao, J., N. Papadopoulou, D. Kempuraj, W. S. Boucher, K. Sugimoto, C. L. Cetrulo, and T. C. Theoharides. 2005. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J. Immunol. 174: 7665-7675.
105. Kempuraj, D., N. G. Papadopoulou, M. Lytinas, M. Huang, K. Kandere-Grzybowska, B. Madhappan, W. Boucher, S. Christodoulou, A. Athanassiou, and T. C. Theoharides. 2004. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145: 43-48.
106. Huang, M., J. Berry, K. Kandere, M. Lytinas, K. Karalis, and T. C. Theoharides. 2002. Mast cell deficient W/Wv mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Int. J. Immunopathol. Pharmacol. 15: 249-254.
107. Cao, J., C. L. Cetrulo, and T. C. Theoharides. 2006. Corticotropin- releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol. Pharmacol. 69: 998-1006.
108. Castagnetta, L., O. M. Granata, A. Traina, L. Cocciadiferro, A. Saetta, R. Stefano, M. Cutolo, and G. Carruba. 2002. A role for sex steroids in autoimmune diseases: a working hypothesis and supporting data. Ann. NY Acad. Sci. 966: 193-203.
109. Vliagoftis, H., V. Dimitriadou, W. Boucher, J. J. Rozniecki, I. Correia, S. Raam, and T. C. Theoharides. 1992. Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int. Arch. Allergy Immunol. 98: 398-409.
110. Narita, S., R. M. Goldblum, C. S. Watson, E. G. Brooks, D. M. Estes, E. M. Curran, and T. Midoro-Horiuti. 2007. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ. Health Perspect. 115: 48-52.
111. Vasiadi, M., D. Kempuraj, W. Boucher, D. Kalogeromitros, and T. C. Theoharides. 2006. Progesterone inhibits mast cell secretion. Int. J. Immunopathol. Pharmacol. 19: 787-794.